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A B S T R A C T
In situ forming hydrogels with simple sol–gel transition are more practicable as injectable
hydrogels for drug delivery and tissue regeneration. State-of-the-art in situ gelling systems
can easily and efficiently be formed by different mechanisms in situ. Chitosan is a kind of
natural polysaccharide that is widely exploited for biomedical applications due to its good
biocompatibility, low immunogenicity and specific biological activities. Chitosan-based in
situ gelling systems have already gained much attention as smart biomaterials in the de-
velopment of several biomedical applications, such as for drug delivery systems and
regeneration medicine. Herein, we review the typical in situ gelling systems based on chitosan
and mechanisms involved in hydrogel forming, and report advances of chitosan-based in
situ gels for the applications in drug delivery and tissue regeneration. Finally, develop-
ment prospects of in situ forming hydrogels based on chitosan are also discussed in brief.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Hydrogels are the polymeric materials with three dimensional
networks, which have gained much attention in biomedical fields
as carriers for drugs, protein, cells, and others because of their
good biocompatibility, solute permeability and tunable release
characteristics [1].The retaining ability of a large amount of water
within their structures which results in high water content and
soft-surface properties is the character that makes them
compromised on the surrounding tissues and leads to a good
biocompatibility. Since the development of hydrogels in 1960s,
numerous studies on adapting hydrogels as biomaterials have
been reported. Especially, the in situ forming hydrogels which
usually show sol-to-gel transition at the in-situ site where they
are administrated into the body, exhibit promising potentials
for clinic applications. It is more practicable to apply in-situ
forming hydrogels to tropical drug delivery, injectable implant,
tissue engineering scaffold and so on [2–5]. The drug/cell can
be mixed with the aqueous sol for convenient administration
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like injection and then a gel depot encapsulating drug/cells is
formed in situ. In situ gelling systems could potentially allevi-
ate several drawbacks associated with contemporary regenerative
medicine approaches and scaffolds. Primarily, they minimize the
invasiveness of the open surgical technique and can conform
to complex 3D geometries, which is critical in implant drug de-
livery system, repair of trauma, and regeneration post-tumor
resection. More importantly, this allows for delivery of cells and
growth factors locally, which could potentially lead to faster and
complete regeneration [6].
Chitosan, the second most abundant natural polysaccha-
rides next to cellulose, has many advantages over other
polymers, like nontoxicity, biocompability and biodegradabil-
ity. Chitosan is a family of cationic polysaccharides with a basic
chemical structure of (1,4)-linked 2-amino-2-deoxy-D-glucans,
which are produced commercially by the partial deacetylation
of chitin obtained from the reprocessing of seafood waste.
Members of the chitosan family differ in terms of their mo-
lecular weight and degree of deacetylation. Chitosan is
biodegradable, as it is broken down in the human system to
harmless products (amino sugars) that can be easily ab-
sorbed. Nowadays, chitosan and its derivates have been
investigated for many diverse medical applications, such as
wound dressings, contact lenses, and materials for cell en-
capsulation, drug delivery and so on [7–9]. Additionally, chitosan
has several active functional groups that allow for protein
binding and an inherent positive charge that is known to stimu-
late cell interactions and differentiation.
By far, chitosan-based hydrogels have proven to be very ef-
ficient for the delivery of biologically active molecules like
insulin, growth factors, and for providing organization of cells
and tissues, due to the possibility to create multilayered system
[10]. There are also many reports about chitosan-based in situ
hydrogels that can be delivered in minimally invasive tech-
niques such as injection, ocular or nasal administration while
protecting drugs or cells from the hostile environment. In this
paper, several typical in situ gelling systems based on chitosan
are reviewed together with their biomedical applications in drug
delivery and tissue regeneration.
2. Mechanisms to generate in situ hydrogels
A gel is defined as a three-dimensional network swollen by a
solvent. Hydrogels are hydrophilic polymeric networks able to
absorb and retain high quantities of water while retaining its
shape. Based on how the network is connected, hydrogels can
be classified into two categories: the chemical hydrogels where
the hydrophilic polymer chains are associated together by co-
valent bonds, and the physical hydrogels by secondary forces,
such as hydrogen bonds, ionic bonds, intermolecular hydro-
phobic association and so on. Mechanisms involved in in situ
gel formation may include the following: gelation in re-
sponse to temperature or pH change, ionic or covalent cross-
linking, solvent exchange or crystallization, or simply thickening
upon removal of the injection shear.
Among them, thermoresponsive gelling polymers [11,12] are
included with unique characters, which usually exhibit phase
change behaviors of sol-to-gel or gel-to-sol transition upon an
increase in temperature, and have gained enormous atten-
tion to form in situ gels with promising biomedical applications.
Commercially available block copolymers of poly(ethylene oxide-
b-propylene oxide-b-ethylene oxide) (PEO-PPO-PEO) are the best-
known examples of thermally gelling polymers. Aqueous
solutions of PEO-PPO-PEO copolymers demonstrate phase tran-
sitions from sol to gel (low temperature sol-gel boundary) and
gel to sol(high temperature gel-sol boundary) with monotoni-
cally increasing temperature when the polymer concentration
is above a critical value. Moreover, biodegradable copolymers
of polyethylene glycol and poly(lactic/glycolic acid) such as
PLGA-PEG-PLGA, PEG-PLGA-PEG, mPEG-b-PCL and so on, were
recently developed also with thermal-responsive sol-to-gel tran-
sition [13–16]. Aqueous solutions of these copolymers form soft
gels at body temperature (37 °C) but flow freely at room tem-
perature. Therefore, subcutaneous injection of the copolymer
formulation resulted in an in situ-forming gel that exhibited
controlled drug release. Formulations are water based, easy to
sterilize by simple filtration of the aqueous solution. Ideally,
the duration of the gel should be matched with its function
as a temporary tissue scaffold or a drug release depot. By op-
timizing the composition of copolymers, injectable scaffolds
with a broad range of gel degradation time can be designed.
Besides the classic systems mentioned above, enzymati-
cally cross-linked hydrogels [17] have emerged recently as in-
situ gelling system with increasing interest, which can be
formed by enzyme-catalyzed mild-cross-linking reactions in
situ. Hydrogels prepared by using enzyme systems like tyrosi-
nases, transferases and lysyl oxidases show interesting
characteristics as dynamic scaffolds and as systems for con-
trolled release. Additionally, unwanted side effects can be
avoided because of the substrate specificity of the enzyme. In
situ cross-linkable gels are based on aqueous mixtures of gel
precursors with bioactive agents that can be administrated via
a syringe. Moreover, injectable enzymatically cross-linked
hydrogels offer a plausible solution for the generation of func-
tional tissue substitutes of these gels and native tissue, therefore
maintaining the cell phenotype, which is highly relevant for
tissues like cartilage. Importantly, the poor or limited me-
chanical properties of some hydrogels can be improved by
combining enzyme types such as transglutaminases and horse-
radish peroxidases systems, after adjusting the material design.
For example, transglutaminases are highly interesting as they
offer intimate integration between the in situ formed gel and
the native host tissue. Engineered peroxidases with higher sta-
bility and catalytic efficiency are currently being developed. In
the near future, further applications using this enzyme type
will be developed and continue to prosper in the tissue engi-
neering field.
3. Typical in situ gelling systems based
on chitosan
According to the mechanism of gel formation, chitosan-
based in-situ gelling systems can be classified into two
categories: in-situ covalent cross-linking system and in-situ
phase separation system.
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3.1. In-situ covalent cross-linking system
In the chemical cross-linking approach, the formation of co-
valent bonds between polymer chains results in gel matrix of
three-dimensional network.There are plentiful of amino groups
(-NH2) and hydroxyl groups (-OH) along the chitosan chain,
which can be used as cross-linkable functional groups to react
with cross-linking agents for in-situ chemical cross-linking.
Genipin is a water-soluble bifunctional cross-linking reagent
derived from gardenia fruit extract (geniposide), the most
popular non-toxic cross-linker to produce chitosan hydrogels.
A series of in situ forming chitosan-based hydrogels have been
prepared by chemical cross-linking of chitosan and genipin
without/with the cooperation of ionic interaction between
chitosan and sodium salts, like sodium orthophosphate hydrate
(Na3PO4), sodium sulfate (Na2SO4), or sodium bicarbonate
(NaHCO3), etc. [18–20]. The gelation time, rheological properties
and morphology of gelling systems varied with the genipin con-
centration, the pH condition as well as the different salts. For
example, the hydrogel composed of chitosan, genipin and
Na3PO4 showed short gelation time of 8 min and non-toxicity
under physiological conditions [18]. It is noted that the cross-
linking reaction mechanisms for chitosan with genipin are
different at different pH values [20]. Under acidic and neutral
conditions, genipin acts as a similar function as dialdehyde un-
dergoing a Schiff reaction with the amino groups on chitosan
and yielding the two newly chemical groups: the monosub-
stituted amide and the tertiary amine, as shown in Fig. 1. Under
basic conditions, genipin formed first homopolymerized ones
to be a cross-linker.Though the mixture of chitosan and genipin
is almost transparent, they produce blue-colored fluorescent
hydrogels after completing sol–gel transition. It is attractive that
genipin is a fully biocompatible reagent, capable of meeting
the scopes of the current biomedical applications based on
chitosan in-situ forming hydrogels. Genipin was also added in
some physical in-situ gelling system (like chitosan/GP system)
to improve the mechanical properties and chemical stability
of hydrogel due to the presence of covalent bonds between the
chitosan and genipin [21].
Moreover, in-situ covalent cross-linking hydrogels may also
be achieved without the additional cross-linkers by attaching
cross-linkable functional groups to chitosan and another
polymer. This approach has been explored by many research-
ers as summarized in Table 1. For example, Schiff’s reaction
between the amino and aldehyde groups is introduced in dif-
ferent systems to form pH-sensitive in situ forming hydrogel
for protein delivery or as wound dressing materials [22–24].The
newly emerged click reactions, like thiol-ene reaction [26,27]
and cyclo-addition [28], are also involved to form chitosan-
based hydrogels due to their high efficiency in mild reaction
conditions. Fabrication of the injectable hydrogels can be modu-
lated from within a minute to hours by controlling the
temperature and pHs of the precursor solution.These hydrogels
prepared via click reaction exhibit controlled architectures and
improved mechanical properties for soft tissue engineering
applications.
Some covalent cross-linking approaches mentioned above
require several hours for gelation. Such slow processes may
impact the functionality of the hydrogel and result in unex-
pected drug release to surrounding tissues. On the other hand,
fast gelation may have difficulty for the mixing and injecting
operations. Thus, photo-induced cross-linking has emerged to
Fig. 1 – Schematic reaction on the cross-linking of two chitosan chains through one molecule of genipin.
Table 1 – Examples of generating chitosan-based in-situ hydrogels through covalent cross-linking of different functional
polymers.
Hydrogel precursors Covalent cross-linking bonds Ref
Chitosan-based derivate Second modified polymer
N,O-carboxymethyl chitosan Oxidized alginate Imine bond [22,23]
Carboxymethyl chitosan Oxidized carboxymethyl cellulose Imine bond [24]
Phenylboronic modified chitosan Oxidized dextran Imine bond and phenylboronate ester [25]
Oxanorbornadiene modified chitosan 11-azido-3,6,9-trioxaundecan-1-amine
modified hyaluronan
The triazole ring formed via a metal-free
click reaction (cyclo-addition)
[28]
Chitosan-acrylate PEO-thiol -S-CH2- formed via thiol-ene reaction [26]
Chitosan–thioglycolic acid Pectin–cysteine Disulfide linkage [29]
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generate in-situ gelation without this conflict. The starting hy-
drogel precursors are liquid solutions that can be injected into
the local site. Upon exposure to light, the injected precursors
polymerize by the initiation of the produced radical species to
form cross-linked polymer network in-situ. Yoon Yeo and co-
workers [30] developed a semi-interpenetrating network (semi-
IPN) by blends of photocross-linkable 4-azidobenzoic acid-
modified chitosan (Az-C) and polyethylene glycol (PEG) as an in-
situ-forming nerve adhesive.The precursor solutions formed soft
gels in <1 min under UV illumination. However, concern may
arise regarding the cytocompatibility of UV-initiating systems
when applied in tissue engineering for direct cell encapsula-
tion in hydrogels. Min Lee et al. [31] recently developed visible
light cross-linkable hydrogel systems using methacrylated glycol
chitosan (MeGC) and three blue light initiators: camphorquinone
(CQ), fluorescein (FR) and riboflavin (RF). A minimal irradiation
time of 120 s was required to produce MeGC gels with CQ or FR,
showing no significant effect on the viability of encapsulated
chondrocytes. It is advanced to apply photoinitiators absorb-
ing in the visible region over UV light-initiated polymerizations,
since exposure to visible light is non-thermogenic and causes
less damage to cells. Nevertheless, caution should be exer-
cised because the reactive species in photopolymerization may
expose free radicals to the surrounding tissues and affect the
incorporated drugs.
3.2. In situ phase-separation system
In-situ phase separation is another strategy utilized widely to
generate in situ gelling system, which can be induced by chang-
ing the solubility of the polymer with respect to changes in
temperature, pH or by elimination of solvent. It is a kind of physi-
cal cross-linking approach to form chitosan hydrogels in situ
by employing secondary bond forces such as hydrogen bonding,
electrostatic interaction, or hydrophobic association. As other
in-situ gelling systems based on the physical cross-linking, the
low mechanical strength of chitosan physical hydrogels and the
impact of the drug and environment on their in-situ gelling pro-
cesses need to be taken into consideration.
3.2.1. Thermal-sensitive gelation system
Thermogel-based platforms undergo sol-to-gel transforma-
tion upon temperature change. Since thermogels do not require
the use of organic solvents, cross-linking agents, or any exte-
rior applied triggers for in-situ gelation, they are especially
attractive for delivery of sensitive small molecules and biological
molecules.The chitosan-based thermogelling systems with the
combinations of chitosan and polyol-phosphates are repre-
sentative ones since they were developed by Chenite et al. in
2000 using β-glycerophosphate (β-GP) as gelling agent [32].
Chitosan is known to be soluble in acidic solutions, and phase
separation happens at pH greater than 6.5. It is interesting that
the acidic chitosan solutions were neutralized by the addi-
tion of polyol-phosphates, but without phase separation at
physiological pH range. These chitosan/polyol-phosphate
systems remain in a liquid state at low temperatures and
undergo sol–gel transition at body temperature. Such chitosan/
polyol-phosphate systems have been extensively studied and
reviewed [33,34], opening doors for the development of par-
enteral drug delivery systems. It was shown that the molecule
weight, deacetylation degree, and concentration of chitosan,
as well as the kind and concentration of polyol-phosphate had
effects on their rheological and physicochemical properties,
and the gelation process. Recently, Nicolas Anton et al. [35] elu-
cidated the gelation mechanism of thermal-sensitive chitosan/
polyol-phosphate systems particularly by comparing β-GP to
glucose-1-phosphate (G1-P) and glucose-6-phosphate (G6-P) and
to a polyol-free phosphate salt, Na2HPO4 as well. As shown in
Fig. 2, polyols create a hydration protective layer around the
chitosan chains, largely built through weak intermolecular in-
teractions, like hydrogen bounds. An increase on temperature
disrupts this polyol layer and allows the polymers to interact
with each other through stronger hydrophobic bonding, thus
inducing the gelation. It was disclosed that the size of the polyol
part had an impact on the stability of this hydration layer, and
thus on the temperature and kinetics of sol–gel transition.
The chitosan/β-GP systems have been proved to be suit-
able in various pharmaceutical and biomedical applications with
promising potentials since GP is a biocompatible component
naturally present in the body approved by the U.S. Food and
Drug Administration [36,37]. However, the long period of time
required for their effective gelation has severely limited their
clinical application. Different strategies have been imple-
mented to improve the hydrogel characteristics such as
replacement of GP, addition of a second polymer and chemi-
cal modification of chitosan, or tailoring the drug release
by combination with carrier particles. For example, the chitosan/
G1-P system exhibited an enhanced stability compared to
the standard chitosan/β-GP system. Chitosan solution with
0.40 mmol/g G1-P is stable for at least 9 months at 2~8 °C
versus less than 1 month of the CS/β-GP system [38]. Indeed,
hydrogels from chitosan/β-GP may lack appropriate mechani-
cal properties for given applications, especially for cell-
carrier systems. To circumvent this problem, several trials
have been evaluated by blending the chitosan/β-GP system
with another biocompatible compound or polymer, such as
g-glycidoxypropyltrimethoxysilane (GPTMS), gelatin, and
hydroxyethyl cellulose (HEC) [39–41]. It is noted that commercial-
grade HEC contains glyoxal, a dialdehyde, which gives rise to
covalent cross-linking of chitosan-GP-HEC hydrogels [41]. In ad-
dition, chemical modification of chitosan has also been reported
to perform modified-chitosan/β-GP systems as thermogelling
solutions. For example, the employment of thiolated chitosan
(CS-TGA) exhibited a sol/gel transition within 2 mins at physi-
ological temperature, an improved mechanical property of
hydrogel and a decreased bovine serum albumin (BSA) release
rate, due to the additional cross-linking by disulfide bonds [42].
Another chitosan-based thermalgelling system has emerged
by the incorporation of hydrophobic n-dodecyl groups in
chitosan following the mixing with β-GP [43], which induced
faster gelation process through formation of smaller but more
homogenous hydrophobic micro-domains with the aid of
pendant hydrophobic moieties in the lower temperature range.
However, there is still a problem with these thermogelling
systems based on chitosan/β-GP system that the excessive use
of glycerophosphate salt may practically limit a number of bio-
medical applications. Alternatively, a series of thermogelling
chitosan derivatives have also been developed, like
hydroxypropyl chitin (HPCh) [44], glycol chitin [45], poly(eth-
ylene glycol) (PEG) grafted chitosan [46] and poly(ethylene
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glycol)-poly(L-alanine-co-L-phenyl alanine) grafted chitosan (CS-
g-(PAF-PEG) [47]. These thermogelling chitosan derivatives are
water-soluble under physiological conditions after the chemi-
cal modification. By varying the polymer concentration, the
molecular parameters of grafted branches (groups), such as their
composition, molecular weight and/or substituted degree, the
sol–gel transition temperature of such thermogelling chitosan
derivative could be tuned to match the different application
requirements, showing good feasibility as an injectable in situ
gelling system. The thermogelation mechanism of CS-g-(PAF-
PEG) was investigated on a molecular level by Byeongmoon
Jeong et al. [47]. It was suggested that an extensive molecular
aggregation might be involved in the sol-to-gel transition, where
the CS-g-(PAF-PEG) formed micelles with 10–50 nm in diameter
at 10 °C and formed large aggregates ranging from hundreds
to thousands of nanometers in size as the temperature in-
creased up to 35 °C.
3.2.2. pH sensitive gelation system
Changing pH is a common approach to perform sol-to-gel tran-
sition for pH-sensitive, water-soluble polymers. They usually
undergo phase transition due to the functional groups on the
polymers that either accept or donate protons as a result of
pH changes in the environment. Chitosan is a cationic poly-
electrolyte, whose solutions would exhibit a liquid–gel transition
around pH 6.5, when pH changes from slightly acidic to neutral.
Increasing the pH will deionize chitosan, thus generating
the three-dimensional chitosan network due to physical
junctions of hydrogen bonds. Based on such mechanism, an
injectable in situ forming system was developed from acidic
chitosan solution with the combination of sodium bicarbon-
ate (NaHCO3) [48]. Similarly, a thermosensitive chitosan gel
containing hydroxyapatite (HA) was prepared using Na2CO3 as
coagulant for bone mesenchymal stem cells (MSCs) loading [49].
It was reported that the chitosan solution remained in a ho-
mogeneous sol state in sealed container at low temperature.
Then, chitosan gels were formed in situ after subcutaneous in-
jections of either the chitosan/ NaHCO3 sol or the chitosan/
HA/Na2CO3 ones in rats. Although their sol-gel transitions
appeared to be thermal-sensitive upon the temperature in-
creasing, these systems performed actually the pH-induced
gelation process. Both NaHCO3 and Na2CO3 are known as a weak
base, and the reaction between [HCO3−] ([CO32−]) and [H+] leads
to the pH increase accompanying with the CO2 emitting and
the hydrogel formation. Such neutralization reaction would
reach different balance depending on the temperature and the
release of CO2, which controlled the sol–gel transition.The com-
position of these in-situ forming systems is simple with no
additives of cross-linking agent or organic solvent, giving rise
to great potential for their biomedical applications.
3.2.3. In situ gelation system through electrostatic interaction
As a cationic polyelectrolyte, the gelation of chitosan can be
induced by adding anionic cross-linker like tripolyphosphate
(TPP) and alginate, as a result of electrostatic attractions. In
this strategy, the cross-linking association occurred usually with
Fig. 2 – Schematic representation of gelation mechanism of thermal-sensitive chitosan/polyol-phosphate systems. Adapted
with permission from [35]. Copyright (2013) American Chemical Society.
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a fast rate, which has been previously used to fabricate chitosan
nanoparticles, microparticles and fibers in many researches.
Recently, Maryam Tabrizian and coworkers [50,51] created a
rapid in-situ gelation system based on chitosan and guano-
sine 5’-diphosphate (GDP), where GDP acted as an anionic cross-
linker. GDP is a cellular component, which cross-linked chitosan
chains very rapidly at the injection location (Tgel < 1.6 seconds)
due to the electrostatic interaction between the anionic phos-
phate groups of GDP and the cationic amine groups of chitosan.
The fast gelation rate of this system could prevent undesir-
able flow to surrounding tissues as injectable carriers. But it
is necessary to design a specific double-barrel syringe with two
independent outlets to mix chitosan and GDP solutions at the
tip of the needle during injection as shown in Fig. 3.This avoids
clogging of the needle and ensures that the mixture and ge-
lation occurs in situ. The obtained hydrogels showed a porous
micro-structure, desirable cytocompatibility and mechanical
properties resembling those of human soft tissue.
4. Applications of in-situ forming chitosan
hydrogel
4.1. Drug delivery
A large amount of pharmaceutical agents have been discov-
ered over the past decades. Many of them possess good
therapeutic effects but their bioavailability and pharmacoki-
netics are poor, showing systemic toxicity after the
administration. Therefore, drug delivery system has become
an important tool to enhance the therapeutic efficiency using
delivery matrices such as nanoparticles, polymeric micelles or
hydrogels to deliver drug molecules. In situ gelling systems,
especially the biodegradable ones are very attractive for local
delivery of drugs, since they can be administrated by injec-
tion showing less invasion and less pain as compared to pre-
formed implants and sustained release of drug [52,53]. Injectable
chitosan-based in situ gelling systems have been applied as
in-situ forming implants and as mucosadhesive carriers in nasal
delivery, ocular delivery and others because of their good tissue
biocompatibility, sustained-release properties and simple
manufacture.
4.1.1. In situ forming implants
In the area of parenteral controlled release formulations, in situ
forming implants are attractive alternatives to the pre-
formed implants and microparticles, which could be injected
as low viscous solutions and transform to a gel or solid depot
in the body at the injection site, thus avoiding the use of large
needles or microsurgery. The in-situ forming gelling systems
consisting of chitosan and β-GP have come into the market as
commercially available delivery platforms (like BST-Gel) for in-
situ forming implants, which can deliver water-soluble small-
molecular drugs, chemotheraputic agents as well as proteins
and peptides.
Peng et al. [54] reported the thermosensitive chitosan/GP
hydrogels for the sustained delivery of venlafaxine hydrochlo-
ride (VH) and the optimization of this formulation. VH is a
water-soluble antidepressant of the serotonin-norepinephrine
reuptake inhibitor (SNRI) class. Both in vitro drug release and
in vivo pharmacokinetic study via subcutaneous administra-
tion were investigated, demonstrating that thermosensitive
chitosan/GP hydrogels had a better sustained delivery of VH
over 24 h compared to VH solution. Dean-Mo Liu et al. [55] de-
scribed a depot drug delivery system by combining self-
assembled nanocapsules of carboxymethyl-hexanoylchitosan
(CHC) with glycerophosphate di-sodium salt and glycerol for
the highly water-soluble drug Ethosuximide (ESM). In this case,
CHC played the role not only to encapsulate the drug, with
reduced burst release and release rate as consequences, but
also to be the gel network forming constituent. In vivo study
through subcutaneously injection using Long Evans Rats as the
animal model demonstrated that therapeutic drug levels of ESM
remained until day 4, in contrast, for free ESM there was a rapid
initial response 1 h after administration.
Additionally, intratumoral injection has served as another
way for in-situ forming implants to deliver anti-tumor drugs,
which can enhance drug bioavailability to the tumor site and
reduce systemic toxicity [2].The chitosan/GP gelling system has
been utilized to deliver several kinds of chemotheraputic agents
such as paclitaxel [56], camptothecin [57], Docetaxel [58],
melphalon [59], curcumin [19] and so on [60], displaying more
efficiency in inhibiting the growth of tumors and less toxic than
single intraperitoneal or intravenous injections. Interestingly,
the chitosan/GP thermogel was also applied as a vehicle of
pingyangmycin (PYM) for the chemoembolization therapy of
vascular malformations (VM) in the research by Chen et al. [61].
The injected solution changed into a semisolid embolic agent,
which showed the dual occlusion mechanism including oc-
cluding blood vessels to interrupt the nutrition supply to VM
and sustained release of PYM to keep an effective therapeutic
concentration. The rabbit in vivo pharmacokinetics study of
PYM loaded thermogels indicated that a small dose of PYM
thermogels could make higher localized drug concentrations
for a longer time and lower drug concentrations of systemic
circulation, compared to PYM injections.
Moreover, a proposal to achieve longer sustained release of
drug in chitosan/β-GP hydrogels is to incorporate the drug into
liposomes, microspheres or nanoparticles at first and then mix
the drug-loaded liposomes with chitosan/β-GP solution. The
Fig. 3 – (A,B) Schematic representation and image of a
double-barrel and double lumen injection system for in-
situ gelation. (C) SEM image of the formed chitosan sponge.
Adapted with permission from [51]. Copyright (2014) Royal
Society of Chemistry.
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release rate of the drug can be tuned by both the properties of
liposomes (size and composition) and the properties of chitosan-
based thermogels.Topotecan hydrochloride (TPT) has potential
for the treatment of ovarian cancer. Scientists have proposed
to incorporate TPT liposomes into injectable thermosensitive
in situ hydrogel, consisting of chitosan and beta-GP, for sus-
tained release and preservation of active lactone form of TPT
[62].The drug release rate of TPT was found to be slowed down
in liposomes-loaded chitosan/GP hydrogel, and the lactone frac-
tion of TPT in the hydrogel matrix remained 40% after 50 h.
Therefore,TPT-liposomes-loaded chitosan/GP hydrogel was dem-
onstrated to be a potential formulation for improving the
antitumor efficacy of TPT and an important technology plat-
form for intratumoral administration of camptothecin-family
drugs. Another injectable hydrogel with an in situ and pH sen-
sitive drug delivery system was developed by mixing conjugated
doxorubicin (DOX) conjugated succinated chitosan (S-chi) with
oxidized alginate and investigated for cancer treatment in the
xenograft breast tumor model [63]. Since DOX was conjugated
to S-chi via a pH-sensitive Schiff base, the DOX laden hydrogel
exhibited a pH sensitive release of DOX upon the stimulus of
an acidic tumor microenvironment and thus significantly in-
hibited tumor growth.
4.1.2. Nasal delivery
Intranasal delivery is one of the most interesting and chal-
lenging endeavors in pharmaceutical fields. It could overcome
the high first-pass metabolism and drug degradation in the gas-
trointestinal environment, but show such drawbacks as short
residence in the nasal cavity, highly variable efficiency, low per-
meability, and inconvenient administration. Attempts have been
made to overcome these drawbacks and to increase the nasal
bioavailability of drugs through use of in situ gelling systems
[5]. In the quest for the development of intranasal hydrogels
for the drug delivery, the in situ forming chitosan hydrogels
have received considerable attention because of the strong
mucoadhesivity of chitosan derivates and its effectiveness at
opening tight junctions between epithelial cells [64–66]. These
in situ gelling systems can carry different drugs through nasal
routes for disease treatment, among which the most com-
monly used are protein drugs like insulin and central nervous
system (CNS) acting drugs like doxepin and ropinirole.
An in situ thermogelling hydrogel based on N-trimethyl
chitosan chloride, glycerophosphate (GP) and poly(ethylene)
glycol (PEG) has been formulated as a carrier matrix for the
transmucosal delivery of insulin via the nasal route [67–69].
By the utilization of such in situ thermogelling hydrogel, the
formulation can be dropped or sprayed easily into nasal cavity
and spread on the nasal mucosa in solution state and then
transformed into viscous hydrogel at body temperature. An in
vivo investigation in a diabetic-rat model demonstrated a de-
creased nasal mucociliary clearance rate and a slow release
of insulin, resulting in the reduction in blood glucose over ca.
24 hours as compared with the subcutaneous insulin control
(maximum reduction of blood glucose of ca. 40% at 1 hour from
administration). Thus, such nasal formulation shows the po-
tential as a once-a-day dosage form for the delivery of insulin.
There is another thermosensitive in situ gel system based on
chitosan and poly vinyl alcohol (PVA) for nasal delivery of insulin
[70]. The hydrogel is prepared by mixing chitosan and PVA. The
in vitro release of insulin from gel network is observed spec-
trophotometrically which is good enough to maintain blood
glucose level for six hours. Furthermore, the formulation when
evaluated for their in vivo hypoglycemic effect, demon-
strated its ability to reduce glucose level. The observed in vitro
and in vivo results indicate that the proposed thermosensitive
in situ gelling system has substantial potential as nasal de-
livery system for insulin.
As for CNS drug delivery, the chitosan/GP based thermogelling
system has been served to delivery doxepin, an agent used in
the treatment of depression, to brain through intranasal ad-
ministration [37]. The prepared systems are evaluated for
different parameters like gelling characteristics, rheological char-
acteristics, in vitro drug release, and ex vivo permeation across
sheep nasal mucosa. According to the results, such chitosan/
GP hydrogels gels have shown good mucoadhesion, enhanced
drug permeation, and provided sustained in vitro release of
doxepin at 37 °C. The prolonged effect of the formulations
endowed the reduced dosing frequency possible and the ef-
fective delivery of doxepin to brain via nose. Another
mucoadhesive in situ gel formulations consisting of chitosan
and hydroxyl propyl ethyl cellulose have been applied to enhance
intranasal delivery of ropinirole (a dopamine D2 agonist in treat-
ment of Parkinson’s disease) to the brain [71]. The high brain
direct drug transport percentage of 90.36% and drug targeting
index (DTI) > 1 confirms direct nose to brain transport of the
intranasal in situ gel formulation of ropinirole.These chitosan-
based in situ gelling systems have been demonstrated to increase
the retention of drugs in the nasal cavity, and some of them
also show permeation-enhancing capabilities, which can serve
as effective systems for delivery of drugs through nose with
increased nasal residence time.
4.1.3. Ocular delivery
Research on chitosan and its derivatives as promoters of in-
traocular penetration of topically administered drugs has been
reported in recent literature [72]. A major problem in ocular
therapeutics with classical formulations is the maintenance
of an effective drug concentration at the site of action for a
long period of time. Chitosan stands out with its unique ad-
vantageous characteristics for different types of formulations
like in situ gelling systems, nanoparticles, inserts, etc [73]. Also
chitosan seems to be one of the most promising polymeric car-
riers for both hydrophilic and lipophilic drugs for ocular
application. The chitosan-based in situ hydrogels have been
adopted in the treatment for age related macular degeneration
(AMD), glaucoma as well as some mucosal allergic diseases.
Avastin® tends to be the first choice drug for the treat-
ment of AMD and proliferative diabetic retinopathy in clinic.
An in situ injectable hydrogel was developed by simple mixing
glycol chitosan and oxidized alginate aqueous solution for po-
tential ocular drug delivery of avastin by Xu et al. [22]. In vitro
degradation test and in vitro release study have demon-
strated that the release rate of avastin from hydrogels declined
accordingly with the increase of oxidized alginate concentra-
tion in the hydrogel, and the encapsulated avastin had an initial
burst release at early stage (within 4 h) followed by a sus-
tained release manner in a period of 3 days. The obtained
injectable polysaccharides cross-linked hydrogel with control-
lable degradation rate and sustained drug release may be a
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versatile carrier for ocular delivery of avastin through intravitreal
injection to treat the posterior diseases.
When it comes to glaucoma therapy, timolol maleate was
formulated by the gelling agent of combining chitosan (a pH-
sensitive polymer) with gellan gum (an ion-activated polymer).
Ocular retention was studied by gamma scintigraphy and a sig-
nificant increase in retention time was observed in the research
[74]. An in situ thermogelling system based on chitosan in com-
bination with disodium alpha-d-Glucose 1-phosphate (DGP) has
also been developed as ocular drug delivery system for
levocetirizine dihydrochloride (LD), which especially does good
to cure mucosal allergic diseases.The developed hydrogel pres-
ents a characteristic of a rapid release at the initial period
followed by a sustained release and remarkably enhances the
cornea penetration of LD [75]. The drug-loaded hydrogel has
produced more effective anti-allergic conjunctivitis effects com-
pared to LD aqueous solution. These results show that that the
chitosan-based in situ gelling system can be a viable alterna-
tive to conventional eye drops for the treatment of various
ocular diseases.
Overall, the potential of chitosan-based formulations has
been confirmed by proving their safety to ocular structures.The
above-mentioned results of ocular irritation have demon-
strated the excellent ocular tolerance of the chitosan-based in
situ hydrogels. Meanwhile, the ocular residence time for the
hydrogel is significantly prolonged compared to eye drops.
4.2. Tissue regeneration
Tissue regeneration is an interdisciplinary field that applies the
principles of engineering and the life sciences toward the de-
velopment of biological substitutes that restore or improve
tissue function. In situ-forming hydrogels have emerged in the
field of tissue regeneration with potential applications, which
can be divided into two main parts: wound dressing materi-
als for wound healing and cell scaffolds in tissue engineering.
Creating new materials that are biodegradable and do not
induce scar tissue formation is a challenging and a new area
of tissue regeneration [76].
4.2.1. Wound dressing material for wound healing
Wound healing is a complex process involving three interre-
lated dynamic and overlapping phases including inflammation,
granulation and remodeling. In this field, numerous materials
have been discovered as wound dressing to promote wound
healing, such as chitosan, hyaluronic acid, poloxamer and so
on [24,77]. We take advantage of chitosan by designing various
types of in situ forming hydrogels, since chitosan itself shows
antibacterial nature and capability to enhance wound healing
and not to induce scar tissue formation.
An in situ gelling system composed of rutin- and tyramine-
conjugated chitosan derivatives, horseradish peroxidase (HRP)
and hydrogen peroxide was reported as injectable dressing for
dermal wound repair [78]. It was found that rutin-conjugated
hydrogel exhibited enhancement of wound healing as com-
pared with treatments with PBS, hydrogel without rutin, and
a commercialized wound dressing (Duoderm). Moreover, an in
situ injectable nano-composite hydrogel composed of N,O-
carboxymethyl chitosan and oxidized alginate (CCS-OA)
encapsulating nano-curcumin has been successfully developed
as a novel wound dressing for the dermal wound repair ap-
plication. Histological study revealed that the application of
nano-curcumin/CCS-OA hydrogel could significantly enhance
the re-epithelialization of epidermis and collagen deposition
in the wound tissue [79]. All these results suggest that the de-
veloped chitosan-based in situ forming hydrogels might have
potential application as a promising wound dressing for wound
healing.
4.2.2. Cell scaffold in tissue engineering
In situ forming hydrogels show interesting characteristics as
dynamic scaffolds to provide 3D network for seed cells and to
provide the less invasive surgical procedures for tissue engi-
neering application. Scaffolds based on chitosan hydrogels have
great potential due to their minimal foreign body reaction, bio-
compatibility, biodegradability, adhesion to cells and the ability
to be molded in various geometries. Especially, the chitosan-
based gelling systems have been applied as injectable scaffold
materials mostly in the regeneration of cartilage [40,80], bone
[26,52,81–84], nerve [51,76] and other soft tissue [85,86].
Hydrogels based on chitosan/GP thermosensitive formula-
tion can be implanted in a minimal invasive manner,
representing a great promise as injectable scaffold choice for
cartilage and bone tissue engineering. However, their poor me-
chanical property is a limitation for cartilage lesions repair as
well as bone repair. Some modified formulations of chitosan/
GP combined with starch were investigated to generate a firm
texture gels encapsulating adipose derived stromal (ADSC) cells
for cartilage-engineered regeneration [80].The storage modulus
of the hydrogels increased within increasing starch concen-
tration. The encapsulated ADSC remained viable and
proliferated within chitosan hydrogels, and maintained the ex-
pression of typical chondrogenic markers genes and deposited
cartilage ECM molecules in vitro, demonstrating the chondro-
genic differentiation of ADSC. In another case, chondrogenic
factors or human mesenchymal stem cells (hMSCs) were in-
cluded in the chitosan-β glycerophosphate-hydroxyethyl
cellulose (CH-GP-HEC) systems, and injected into the site of
injury to fill the cartilage tissue defects using minimal inva-
sive techniques [40]. During the 28-day investigation, chitosan-
based injectable hydrogels provided suitable conditions for
chondrogenic differentiation of the encapsulated hMSCs.
Regarding the complex features of bone tissue, the com-
posite materials combining of inorganic ceramic materials with
organic hydrogels are highly advantageous for bone tissue re-
generation. Dessi et al. [82] prepared thermosensitive chitosan-
based hydrogels, cross-linked with β-glycerophosphate and
reinforced via physical interactions with β-tricalcium phos-
phate (β-TCP) as promising candidates for injectable in situ
gelling bone analogues. Moreover, in order to enhance osteo-
genic differentiation of seed cells, an ideal scaffold should also
provide controlled release of the active substance. Therefore,
a serial of composite materials were reported in the litera-
ture in order to enhance antibacterial activity and maximize
bone induction, like the chitosan–collagen composite hydrogels
[84], the demineralized bone matrix (DBM) powder loaded
thermogelling chitosan [83], the zinc doped chitosan/GP hy-
drogel [81] and the in situ chitosan–PEO hydrogel containing
recombinant human bone marrow protein-2 (rhBMP-2) [26].
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Moreover, injectable hydrogels offer a more applicable strat-
egy for soft tissue regeneration, by which an easy and
homogenous drug or cell distribution could be performed within
any defect size or shape. For example, Valmikinathan CM et
al. [76] designed the photocross-linkable chitosan hydrogels to
encapsulate neural stem cells (NSCs), which facilitated the dif-
ferentiation of NSCs into tubulin positive neurons and astrocytes
and proved to be a suitable scaffold for neural tissue engineering.
5. Conclusion and prospects
In-situ gelling system is a minimally invasive and interesting
solution in the development of drug delivery and tissue en-
gineering approaches. Various in-situ forming hydrogels based
on chitosan have been designed as injectable hydrogels-
based devices for in situ drug or cell release, which rheological
or mechanical and functional features could be tailored and
enhanced by the composites and methods modification.
In fact, the drug delivery and scaffold could be consistent
in the field of tissue engineering. The key point in tissue en-
gineering is to construct a suitable microenvironment which
includes mechanical strength, growing factors, and others for
seed cells to grow, ensuring their long-term survival and further
differentiation in vivo.Three dimensional porous scaffolds with
growing factors are commonly used in the field of tissue en-
gineering. In situ forming chitosan hydrogels can be used not
only as exogenous implant carrier of seed cells but as the carrier
for controlling the release of growing factors as well. However,
if we carry the growing factors directly inside the chitosan
hydrogels, several drawbacks emerge, like very fast releasing
rate. It is always a difficult and hot spot in tissue engineering
that the additive cell growing factors play the role in a timely
and appropriate way effectively in order to promote cell pro-
liferation and directional differentiation and benefit the
reconstruction of damaged tissues. Organic combination of
novel growing factors controlling release systems based on
chitosan microspheres, chitosan nanoparticles, chitosan
nanoparticle gene complexes and chitosan-based in situ gelling
systems turns out to be a possible solution to solve the above-
mentioned problems. Therefore, the combination of drug
delivery system and tissue engineering scaffold based on in
situ chitosan hydrogels is expected to enjoy a definite prom-
ising prosperity in the medical field.
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